Recursion Pharmaceuticals Inc. - 2026年季度报告

FORM 10-Q TABLE OF CONTENTS Part IFinancial Information Cautionary Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains “forward-looking statements” about us and our industry within the meaning ofSection 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” •the initiation, timing, progress, results, and cost of our current and future preclinical and clinical studies, including statementsregarding the design of, and the timing of initiation and completion of, studies and related preparatory work, as well as the collaborations; •our ability to use our combined assets from our business combination to create a fully integrated, technology-first drug discovery platform; •our ability to reduce our cash burn; •the timing and likelihood of our ability to shift our wet-lab from a source of data generation to a model for validating data fromAI-generated results and the projected impact of our ClinTech platform on our business; •the ability and willingness of our collaborators to continue research and development activities relating to our development candidates and investigational medicines;•future agreements with third parties in connection with the commercialization of our investigational medicines and any other approved product; •the timing, scope, and likelihood of regulatory filings and approvals, including the timing of Investigational New Drugapplications and final approval by the U.S. Food and Drug Administration, or FDA, of our current drug candidates and any other future drug candidates, as well as our ability to maintain any such approvals;•the timing, scope, or likelihood of foreign regulatory filings and approvals, including our ability to maintain any such approvals; •the size of the potential market opportunity for TechBio companies, including the expected impact of AI-enabledtechnologies; •the size of the potential market opportunity for our drug candidates, including our estimates of the number of patients whosuffer from the diseases we are targeting; •our ability to identify viable new drug candidates for clinical development and the rate at which we expect to identify suchcandidates, whether through an inferential approach or otherwise; •our expectation that the assets that will drive the most value for us are those that we will identify in the future using ourdatasets and tools; •our ability to develop and advance our current drug candidates and programs into, and successfully complete, clinicalstudies; traditional drug discovery paradigm, including the use of data sets from our partners to accelerate the development of our AI-enabled technologies; •our ability to improve, and the rate of improvement in, our infrastructure, datasets, biology, technology tools, and drug discovery platform, and our ability to realize benefits from such improvements; •our ability to effectively use machine learning and artificial intelligence in our drug development process;•our ability to leverage our collaborations and partnerships to develop our products and grow our business;•our expectations related to the performance and benefits of our BioHive-2 supercomputer, Recursion OS, and our digitalchemistry platform; •our ability to realize a return on our investment of resources and cash in our drug discovery collaborations;•our ability to sell or license assets and re-invest proceeds into funding our long-term strategy;•our ability to scale like a technology company and to add more programs to our pipeline each year;•our ability to acquire and generate datasets to train and develop our AI-enabled technologies;•our ability to successfully compete in a highly competitive market;•our manufacturing, commercialization, and marketing capabilities and strategies;•our plans relating to commercializing our drug candidates, if approved, including the geographic areas of focus and sales strategy; •our expectations regarding the approval and use of our drug candidates in combination with other drugs;•the rate and degree of market acceptance and clinical utility of our current drug candidates, if approved, and other drugcandidates we may develop; •our competitive position and the success of competing approaches that are or may become available, including with respect to our AI-enabled technologies;•our estimates of the number of patients that we will enroll in our clinical trials and the timing of their enrollment;•the beneficial characteristics, safety, efficacy, and therapeutic effects of our drug candidates;•our plans for further development of our drug candidates, including additional indications we may pursue;•our ability to adequately protect and